Stoney. I follow about 5 or 6 small cap bios some for years without investing, I like most have investment rules.
2 rules which I share with quite a few other people {and groups of people if you take the hint} is never invest in any small biotech which is > 12 months away from being profitable.
The other is do they have the funds to deliver that profitability without going to the market again.
AHZ might be a case where thru frustration those that invested way too early, not aware of investment rules restricting much larger amounts of funds which are only now becoming aware of this stock for the 1st time.
There has been some large selling over last couple of months that to be honest I cannot get a handle on.
Despite this I'm cautiously accumulating.
r
Ann: Admedus Finishes 2016 with Growing Revenue, page-107
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |